{
  "denotations": [
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 52,
        "end": 61
      }
    },
    {
      "id": "T2",
      "obj": "Chemical",
      "span": {
        "begin": 66,
        "end": 75
      }
    },
    {
      "id": "T4",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 134,
        "end": 138
      }
    },
    {
      "id": "T5",
      "obj": "Disease",
      "span": {
        "begin": 109,
        "end": 114
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "20973798_3",
  "text": "Pooled data from several phase II studies show that gefitinib and erlotinib induce responses in over 70 % of NSCLC patients harboring EGFR mutations , with progression-free survival ( PFS ) ranging from 9 to 13 months ."
}
